Cardiovascular Health in Women with Polycystic Ovary Syndrome

Sara Sukalich; David Guzick

doi:10.1055/s-2003-43309

Seminars in Reproductive Medicine, Inhaltsverzeichnis

Semin Reprod Med 2003; 21(3): 309-316
DOI: 10.1055/s-2003-43309

Cardiovascular Health in Women with Polycystic Ovary Syndrome

Sara Sukalich, David Guzick

Department of Obstetrics and Gynecology, University of Rochester School of Medicine and Dentistry, Rochester, New York

Abstract

ABSTRACT

Polycystic ovary syndrome (PCOS) is arguably the most common endocrinopathy among women of reproductive age. Women with PCOS have clinical characteristics that are associated with insulin resistance, vascular dysfunction, hypertension, and dyslipidemia. Although definitive data for increased cardiovascular events in women with PCOS are lacking, case-control studies have documented an increased risk of preclinical cardiovascular disease. Thus, PCOS should be viewed as a chronic condition that may ultimately have long-term health impacts and patients should be counseled to reduce cardiovascular risk factors through weight control, exercise, and/or pharmacologic treatments.

KEYWORDS

Polycystic ovary syndrome - cardiovascular disease - dyslipidemia - insulin resistance

Volltext

Referenzen

REFERENCES

1 Stein I F, Leventhal M L. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol . 1935; 29 181-191
2 Knochenhauer E S, Key T J, Kahsar-Miller M. et al . Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab . 1998; 83 3078-3082
3 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev . 1997; 18 774-800
4 Wild R, Painter P, Coulson P. et al . Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab . 1985; 61 946-951
5 Talbott E, Guzick D, Clerici A. et al . Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol . 1995; 15 821-826
6 Mahabeer S, Naidoo C, Norman R. et al . Metabolic profiles and lipoprotein lipid concentrations in non-obese and obese patients with polycystic ovarian disease. Horm Metab Res . 1990; 22 537-540
7 Wild R, Bartholomew M. The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome. Am J Obstet Gynecol . 1988; 159 423-427
8 Talbot E, Clerici A, Berga S. et al . Adverse lipid and coronary heart disease profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol . 1998; 51 415-422
9 Dejager S, Pichard C, Bruckert E. et al . Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf) . 2001; 54 455-462
10 Austin M, Breslow J, Hennekens C. et al . Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA . 1988; 260 1917-1921
11 Slowinska-Srzednicka J, Zgliczynski S, Wierzbicki M. et al . The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. J Endocrinol Invest . 1991; 14 569-575
12 Wild R, Alaupovic P, Parker I. Lipid and apolipoprotein abnormalities in hirsute women I: the association with insulin resistance. Am J Obstet Gynecol . 1992; 166 1191-1197
13 Reaven G, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med . 1996; 334 374-381
14 Talbott E, Zborowski J, Sutton-Tyrrell K. et al . Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am . 2001; 28 111-133
15 Dahlgren E, Jahansson S, Lindstedt G. et al . Women with polycystic ovary syndrome wedge resected in 1956 to 1965; a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril . 1992; 57 505-513
16 Rich-Edwards J, Solomon C, Dunaif A. et al .Associations of menstrual cycle characteristics with risk of hypertension in adult women. Presented at the 6th Annual Congress on Women's Health, Washington, DC, 1998
17 Dunaif A, Segal K, Futterweit W. et al . Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes . 1989; 38 1165-1174
18 BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med . 1996; 335 217-225
19 Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med . 1995; 98 33S-39S
20 Legro R, Kunselman A, Dodson W. et al . Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab . 1999; 84 165-169
21 Solomon C, Rich-Edwards J, Dunaif A. et al .Abnormal menstrual cycle length predicts subsequent non-insulin-dependent diabetes mellitus. Presented at the 31st Annual Meeting of the Society for Epidemiologic Research, Chicago, IL, The Johns Hopkins University School of Hygiene and Public Health, 1998, p S60
22 Mather K, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril . 2000; 73 150-156
23 Folsom A, Pankow J, Williams R. et al . Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study. Thromb Haemost . 1998; 79 400-404
24 Talbott E, Zborowski J, Guzick D. et al .Increased PAI-1 levels in women with polycystic ovary syndrome: evidence for a specific "PCOS effect" independent of age and BMI. In: Programs and Abstracts of the 40th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association, San Diego, CA 2000, p 13
25 Atiomo W, Fox R, Conodon J. et al . Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) . 2000; 52 487-492
26 Yarali H, Yildirir A, Aybar F. et al . Diastolic dysfunction and increase serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertil Steril . 2001; 76 511-516
27 Guzick D, Talbott E, Sutton-Tyrrell K. et al . Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol . 1996; 174 1224-1232
28 Young W, Goffman J, Tandy R. et al . The quantification of atherosclerosis, part III: the extent of correlation of degrees of atherosclerosis within and between the coronary and cerebral vascular beds. Am J Cardiol . 1960; 6 300-308
29 Talbott E, Guzick D, Sutton-Tyrrell K. et al . Evidence for an association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol . 2000; 20 2414-2421
30 Rumberger J, Simon D, Fitzpatrick L. et al . Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation . 1995; 92 2157-2162
31 Wexler L, Brundage B, Crouse J. et al . Coronary artery calcification, pathophysiology, epidemiology, imaging methods and clinical implications. Circulation . 1996; 94 1175-1192
32 Christian R, Dumesic D, Yrtiska T. et al .Clinical hyperandrogenism and body mass index predict coronary calcification in premenopausal women with polycystic ovary syndrome. Presented at the Endocrine Society Annual Meeting, Toronto, Canada, June 21-24, 2000
33 Harizi R, Bianco J, Alpert J. Diastolic dysfunction of the heart in clinical cardiology. Arch Intern Med . 1988; 148 99-109
34 Paradisi G, Steinberg H O, Shepard M. et al .Polycystic ovary syndrome is associated with endothelial dysfunction. In: Programs and Abstracts of the 58th Annual Scientific Sessions of the ADA Diabetes 1998 47: A309
35 Birdsall M, Farquhar C, White H. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med . 1997; 126 32-35
36 Wild R, Grubb B, Hartz A. et al . Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril . 1990; 54 254-259
37 Pierpoint T, McKeigue P, Isaacs A. et al . Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol . 1998; 51 581-586
38 Wild S, Pierpoint T, McKeigue P. et al . Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up a retrospective cohort study. Clin Endocrinol (Oxf) . 2000; 52 595-600
39 Adashi E, Rock J, Guzick D. et al . Fertility following bilateral ovarian wedge resection: a critical analysis of 90 consecutive cases of the polycystic ovary syndrome. Fertil Steril . 1981; 36 320-325
40 Gjonnaess H. Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome. Fertil Steril . 1998; 69 697-701